![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ARIAD V LILLY, PART II: THE NEXT BIG PATENT BATTLE
ARIAD V LILLY, PART II: THE NEXT BIG PATENT BATTLE
August 7, 2006
The bell's about to sound for the next round in a patent fight that the entire pharmaceutical industry is watching. Next week the biotechnology firm Ariad Pharmaceuticals and the big drugmaker Eli Lilly & Co. head back to court in a fight over a patent that Ariad claims gives it rights to a drug pathway.
The pathway is the specific way a drug works in the human body. This is a highly
unusual case since patents tend to cover a drug's composition, not the way it
affects the body.
CNN
Money
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct